These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 20724509)
21. Type III Secretion in the Melioidosis Pathogen Vander Broek CW; Stevens JM Front Cell Infect Microbiol; 2017; 7():255. PubMed ID: 28664152 [No Abstract] [Full Text] [Related]
22. Characterization of the capsular polysaccharide of Burkholderia (Pseudomonas) pseudomallei 304b. Masoud H; Ho M; Schollaardt T; Perry MB J Bacteriol; 1997 Sep; 179(18):5663-9. PubMed ID: 9294419 [TBL] [Abstract][Full Text] [Related]
23. Comprehensive identification of virulence factors required for respiratory melioidosis using Tn-seq mutagenesis. Gutierrez MG; Yoder-Himes DR; Warawa JM Front Cell Infect Microbiol; 2015; 5():78. PubMed ID: 26583079 [TBL] [Abstract][Full Text] [Related]
24. In vivo Distribution and Clearance of Purified Capsular Polysaccharide from Burkholderia pseudomallei in a Murine Model. Nualnoi T; Kirosingh A; Pandit SG; Thorkildson P; Brett PJ; Burtnick MN; AuCoin DP PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005217. PubMed ID: 27941991 [TBL] [Abstract][Full Text] [Related]
25. Global map of growth-regulated gene expression in Burkholderia pseudomallei, the causative agent of melioidosis. Rodrigues F; Sarkar-Tyson M; Harding SV; Sim SH; Chua HH; Lin CH; Han X; Karuturi RK; Sung K; Yu K; Chen W; Atkins TP; Titball RW; Tan P J Bacteriol; 2006 Dec; 188(23):8178-88. PubMed ID: 16997946 [TBL] [Abstract][Full Text] [Related]
26. The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. DeShazer D; Brett PJ; Woods DE Mol Microbiol; 1998 Dec; 30(5):1081-100. PubMed ID: 9988483 [TBL] [Abstract][Full Text] [Related]
27. Detection and Quantification of the Capsular Polysaccharide of Burkholderia pseudomallei in Serum and Urine Samples from Melioidosis Patients. DeMers HL; Nualnoi T; Thorkildson P; Hau D; Hannah EE; Green HR; Pandit SG; Gates-Hollingsworth MA; Boutthasavong L; Luangraj M; Woods KL; Dance D; AuCoin DP Microbiol Spectr; 2022 Aug; 10(4):e0076522. PubMed ID: 35924843 [TBL] [Abstract][Full Text] [Related]
28. Pathogenesis of Burkholderia pseudomallei and Burkholderia mallei. Larsen JC; Johnson NH Mil Med; 2009 Jun; 174(6):647-51. PubMed ID: 19585782 [TBL] [Abstract][Full Text] [Related]
29. [Burkholderia mallei and Burkholderia pseudomallei. Study of immuno- and pathogenesis of glanders and melioidosis. Heterologous vaccines]. Manzeniuk IN; Galina EA; Dorokhin VV; Kalachev IIa; Borzenkov VN; Svetoch EA Antibiot Khimioter; 1999; 44(6):21-6. PubMed ID: 10422574 [TBL] [Abstract][Full Text] [Related]
30. Human Immune Responses to Melioidosis and Cross-Reactivity to Low-Virulence Burkholderia Species, Thailand Rongkard P; Kronsteiner B; Hantrakun V; Jenjaroen K; Sumonwiriya M; Chaichana P; Chumseng S; Chantratita N; Wuthiekanun V; Fletcher HA; Teparrukkul P; Limmathurotsakul D; Day NPJ; Dunachie SJ Emerg Infect Dis; 2020 Mar; 26(3):463-471. PubMed ID: 32091359 [TBL] [Abstract][Full Text] [Related]
35. Attenuation of a select agent-excluded Burkholderia pseudomallei capsule mutant in hamsters. Gutierrez MG; Warawa JM Acta Trop; 2016 May; 157():68-72. PubMed ID: 26836271 [TBL] [Abstract][Full Text] [Related]
36. Functional characterizations of effector protein BipC, a type III secretion system protein, in Burkholderia pseudomallei pathogenesis. Kang WT; Vellasamy KM; Chua EG; Vadivelu J J Infect Dis; 2015 Mar; 211(5):827-34. PubMed ID: 25165162 [TBL] [Abstract][Full Text] [Related]
37. Development of novel animal infection models for the study of acute and chronic Burkholderia pseudomallei pulmonary infections. van Schaik E; Tom M; DeVinney R; Woods DE Microbes Infect; 2008 Oct; 10(12-13):1291-9. PubMed ID: 18707015 [TBL] [Abstract][Full Text] [Related]